By inhibiting immunological checkpoints like cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1), these blockers activate the cytotoxic function of T-cells targeting cancer cells, resulting in long-lasting and effective responses in certain patients [24]. This evidence concerns the gene CTLA4 and cancer.